Unparalleled Experience:
We've supported over 30 obesity clinical trials evaluating GLP-1 RAs, including pivotal studies leading to regulatory approvals, in addition to over 40 trials in both diabetes and cardiovascular disease.
Global Reach:
Our solutions for obesity clinical trials have engaged over 50,000 patients across 35 countries, with studies lasting up to 5 years.
Comprehensive ePRO Portfolio:
We have experience in supporting a wide range of ePRO measures to assess aspects of health important to patients with these diseases including:
Health-related quality of life (HRQoL, e.g., SF-36, Impact of Weight on Quality of Life-Lite (IWQoL-Lite)(EQ-5D-5L), Food craving (e.g., Control of Eating Questionnaire (CoEQ)), Mental health (e.g., Columbia-Suicide Severity Rating Scale (C-SSRS), Patient Health Questionnaire-9 (PHQ-9)) and other measures such as the Patient Global Impression of Severity/Change (PCIS/C).
Patient-Centric Design:
Our user-friendly ePRO app not only provides an easy and quick way to collect patient-reported outcomes data, but it also helps to guide each patient through each stage of the study by providing up-to-date clinic visit schedules, visit reminders, study information including what to expect at each clinic visit, and easy to use TeleVisit functionality for remote follow up consultations.
